Inside the MHRA's Crackdown on Illegal Retatrutide and Tirzepatide Manufacturing
TL;DR: MHRA dismantled 3 illegal UK factories making fake retatrutide/tirzepatide pens in 2025-26, seizing 14,000+ doses.
What Has the MHRA's Criminal Enforcement Unit Uncovered Since October 2025?
Between October 2025 and May 2026, the MHRA's Criminal Enforcement Unit (CEU) dismantled three separate illegal UK operations manufacturing or distributing counterfeit injection pens marketed as retatrutide and tirzepatide — a Northampton warehouse, linked premises in Lincolnshire and Nottinghamshire, and a country estate, again near Northampton.[1][2] Across the three raids, officers recovered more than 14,000 doses of unlicensed weight-loss injectables, tens of thousands of empty pens awaiting filling, raw chemical ingredients, packaging lines and manufacturing equipment.
The pattern the MHRA describes is an escalating one: each raid targeted premises the agency links to the same wider criminal network, and the most recent operation, in May 2026, produced the largest single seizure the CEU has recorded.[1] None of the products seized had passed any regulatory testing, quality control or manufacturing licensing — they were sold to consumers as finished medicines with no verified content, purity or dosing accuracy.
What Happened at the October 2025 Northampton Warehouse Raid?
What happened: CEU officers, supported by Northamptonshire Police, raided a warehouse on the outskirts of Northampton over a two-day operation beginning 22 October 2025, identifying what the MHRA described as the UK's first known illicit weight-loss medicine manufacturing facility.[3]
What was seized: More than 2,000 unlicensed retatrutide and tirzepatide pens ready for dispatch to customers, tens of thousands of empty pens awaiting filling, raw chemical ingredients, sophisticated packaging and manufacturing equipment, and roughly £20,000 in cash suspected to be linked to medicines trafficking.[3]
Scale: Press coverage at the time described it as the largest single seizure of trafficked weight-loss medicines recorded by any law-enforcement agency worldwide, with an estimated street value of more than £250,000.[3]
Officials characterised the operation as a significant early win. Press reporting quoted Andy Morling, Head of the MHRA's Criminal Enforcement Unit, calling the result "a landmark result for the MHRA and a major blow to the illegal trade," and stating that stopping tens of thousands of potentially unsafe products from reaching the public had prevented a serious risk to health.[3]
What Happened at the February 2026 Lincolnshire and Nottinghamshire Raids?
What happened: The MHRA, supported by Lincolnshire Police, Immigration Enforcement and Lincolnshire Trading Standards, searched a farm near Sleaford and a residential address in Grantham (Lincolnshire), plus a further Nottinghamshire property, as part of an ongoing investigation into an organised criminal group.[2]
What was seized: Almost 2,000 doses of unauthorised weight-loss medicines awaiting dispatch to customers, alongside manufacturing equipment, suspected pharmaceutical ingredients, packaging materials and commercial vehicles.[2]
Official framing: The MHRA's own press release describes this as disrupting a "second manufacturing facility" tied to the same network first identified in Northampton in October 2025 — language that positions the two operations as connected, not isolated incidents.[2]
What Happened at the May 2026 Raid — the MHRA's Largest Seizure Yet?
What happened: MHRA officers raided a country estate near Northampton and arrested two men, both aged 29, on suspicion of offences under the Human Medicines Regulations 2012.[1] The property is believed to have been used to manufacture, assemble and distribute unlicensed weight-loss medicines and other peptide products at scale.
What was seized: Around 12,000 doses of unlicensed weight-loss medicines — including retatrutide and tirzepatide pens — plus tens of thousands of empty pens ready for filling, raw chemical ingredients and packaging equipment, with a suspected value exceeding £250,000.[1]
Significance: The MHRA described this as its largest ever seizure of unlicensed weight-loss medicines, and the first of the three operations to result in arrests under the Human Medicines Regulations 2012.[1]
| Raid | Date | Doses seized | Arrests |
|---|---|---|---|
| Northampton warehouse | Oct 2025 | 2,000+ pens | None reported |
| Lincolnshire & Nottinghamshire | 25 Feb 2026 | ~2,000 doses | None reported |
| Northampton country estate | 28 May 2026 | ~12,000 doses | 2 (age 29) |
Table for research reference only; figures as reported by MHRA press releases and UK trade press coverage.
How Does This Fit the MHRA's Wider 2025 Enforcement Record?
These three raids are not isolated events. The MHRA's own published 2025 enforcement summary reported almost £45 million in illegally traded medicines seized across the year — nearly 20 million doses in total — including more than 5,000 illegally traded GLP-1-class weight-loss products, with the October Northampton warehouse raid cited as a headline case.[4] The same report noted the CEU worked with internet service providers to disrupt over 1,500 websites and social media accounts illegally selling medical products, and denied criminals access to more than £2.1 million in assets linked to the illegal medicines trade.[4]
Read together with our earlier coverage of Ireland's HPRA warning after a black-market retatrutide hospitalisation, and the MHRA's own Yellow Card adverse-event data for licensed GLP-1 medicines, these raids form part of a consistent regulatory picture across the British Isles: rapid growth in demand for GLP-1-class weight-loss compounds has been matched by rapid growth in illegal, unverified supply.
Why Is Illegal Manufacturing of Retatrutide and Tirzepatide Happening at This Scale?
High consumer demand, no UK licence for retatrutide
Retatrutide is not yet MHRA-approved for any use, while tirzepatide (Mounjaro) is licensed but expensive and supply-constrained, creating a gap that illegal manufacturers fill with counterfeit product marketed as either compound.
No verification of contents
None of the pens seized across these three raids had undergone any legitimate quality testing. The MHRA has previously found detained "GLP-1" products that did not contain the active ingredient claimed on the label.
Organised, not opportunistic
The MHRA's own language — describing the February 2026 raid as disrupting a "second manufacturing facility" — indicates these operations are treated as one connected criminal network under ongoing investigation, not unrelated one-off incidents.
These are finished consumer products, not research reagents. Every pen described in this article was manufactured and packaged to be injected by a consumer as a purported medicine, with no batch documentation, no third-party purity verification and no regulatory oversight of any kind. This is categorically different from an HPLC-verified research chemical sold in lyophilised form to a laboratory for in vitro study.
Does This Affect Legitimate UK Research-Reagent Supply?
No. These raids targeted criminal operations manufacturing and distributing finished injectable products sold to consumers as purported weight-loss medicines — a completely different supply chain, customer base and legal category from HPLC-verified research reagents sold to laboratories for in vitro study. Velox Peptides supplies retatrutide and tirzepatide as lyophilised research chemicals with batch-level Certificates of Analysis, never as finished, ready-to-inject consumer products, and never marketed or intended for human or veterinary use. See our guide on whether research peptides are legal in the UK for the regulatory distinction between a research reagent and a medicinal product under the Human Medicines Regulations 2012.
Retatrutide and tirzepatide are supplied by Velox Peptides as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- GOV.UK / MHRA. Two arrested during the MHRA's largest ever seizure of unlicensed weight loss medicines. Press release, 28 May 2026. gov.uk
- GOV.UK / MHRA. MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines in latest blow to criminal network. Press release, 25 February 2026. gov.uk
- Diabetes.co.uk. MHRA smashes first illicit weight loss jab factory in record raid. October 2025. diabetes.co.uk
- GOV.UK / MHRA. MHRA seizes illegal medicines worth almost £45m in 2025 – disrupting major criminal networks. Annual enforcement summary. gov.uk
- Velox Peptides. See our HPRA Ireland black-market retatrutide warning and MHRA Yellow Card GLP-1 report for related UK/Ireland regulatory context.
Frequently Asked Questions
What has the MHRA's Criminal Enforcement Unit uncovered since October 2025?
Since October 2025, MHRA officers have dismantled three separate illegal UK operations manufacturing or distributing counterfeit retatrutide and tirzepatide injection pens: a Northampton warehouse (October 2025), linked premises in Lincolnshire and Nottinghamshire (25 February 2026), and a country estate near Northampton (28 May 2026). Combined, the three raids recovered more than 14,000 doses, tens of thousands of empty pens, raw chemical ingredients and manufacturing equipment.
What happened at the October 2025 Northampton raid?
MHRA Criminal Enforcement Unit officers, supported by Northamptonshire Police, raided a warehouse in Northampton and identified the UK's first known illicit weight-loss medicine manufacturing facility. They recovered more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch, tens of thousands of empty pens, raw chemical ingredients, packaging and manufacturing equipment, and roughly £20,000 in suspected trafficking cash.
What happened at the May 2026 raid, and why is it called the MHRA's largest ever seizure?
On 28 May 2026, MHRA officers raided a country estate near Northampton and arrested two 29-year-old men under the Human Medicines Regulations 2012. Officers recovered around 12,000 doses of unlicensed weight-loss medicines, including retatrutide and tirzepatide pens, alongside empty pens, raw ingredients and packaging equipment, with a suspected street value exceeding £250,000 — the largest single seizure of its kind the agency has recorded.
Is this part of a wider MHRA enforcement pattern?
Yes. The MHRA's published 2025 enforcement summary reported almost £45 million in illegally traded medicines seized across the year, including more than 5,000 illegally traded GLP-1-class weight-loss products, with the Northampton warehouse raid cited as a headline case. The February and May 2026 raids were explicitly framed by the MHRA as continuations of that same criminal-network investigation.
Does this affect Velox Peptides' UK research-reagent supply?
No. These raids targeted criminal operations manufacturing counterfeit injectable pens sold to consumers as finished weight-loss medicines — a completely different supply chain from HPLC-verified research reagents sold for in vitro laboratory use. Velox Peptides supplies retatrutide and tirzepatide as batch-documented research chemicals only, never as finished injectable products and never for human use. Read the retatrutide research overview →